Sign in
Taking people in SpainPhase 3

Danicamtiv over the long term in adults with inherited dilated cardiomyopathy

Tests danicamtiv's long-term safety in adults with symptomatic genetic or familial dilated cardiomyopathy.

Key facts

Who runs it
Kardigan Inc.
Where
A Coruna, Barcelona, L'hospitalet De Llobregat, Majadahonda, Málaga, Murcia, Palma, and Sevilla, SpainSee the 8 sitesAlso in 8 other countries, 31 sites
Trial code
Registry title
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
Status
Recruiting
Phase
Phase 3
People taking part
211 people, planned
Started
15 Oct 2026
Expected to end
6 Nov 2032
Type of study
Interventional
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with symptomatic genetic and familial dilated cardiomyopathy who completed the DAN-301 study. It looks at the long-term safety of danicamtiv.

Age
18 years and older.
Sex
All sexes can join.
Disease stage
Symptomatic genetic and familial dilated cardiomyopathy, a weakened and enlarged heart muscle that runs in families.
Earlier treatment
People must have completed 24 weeks of blinded study treatment (the Week 26 Visit) and planned assessments in Part 1 or Part 2 of the DAN-301 study.

Main reasons for not taking part

  • Heart attack-type event, heart artery procedure, stroke, or hospital stay or IV diuretic for worse heart failure in the last 90 days.
  • Has a heart pump (ventricular assist device), or a heart pump, heart transplant, CRT or major surgery planned in the next 6 months.
  • Active liver disease, severe kidney problems, or cancer needing treatment after joining DAN-301 that could shorten life.
  • Life expectancy less than 6 months.
  • Pregnant or breastfeeding.

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Is an adult ≥18 years of age at the Screening visit
  • Participants must have completed 24 weeks of blinded study treatment (corresponding to the Week 26 Visit in DAN-301) and planned assessments in Part 1 or Part 2 of the DAN-301 study
  • Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants, if sexually active, must use a highly effective birth control methods listed in the protocol from the Screening visit through 3 months after the last dose of Investigational Medicinal Product
  • Is able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to local and institutional guidelines before the first study-specific procedure

Who cannot take part

  • Participated in a clinical trial (excluding DAN-301 study) in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to enrollment, or less than 5 times the respective elimination half-life (whichever is longer)
  • Participant is on prohibited medication at the time of enrollment
  • Recent (<90 days) acute coronary syndrome or hemodynamically significant epicardial coronary disease or coronary revascularization
  • Has active liver disease
  • Has hypersensitivity to danicamtiv or any of the components of the danicamtiv formulation
  • Recent (<90 days) hospitalization for worsening heart failure (HF) or use of intravenous (IV) diuretic
  • Hospitalization for sepsis or other systemic infections within 30 days of Screening
  • Any malignancy requiring treatment after enrollment in DAN-301 that could limit patient’s survival
  • Severe renal insufficiency
  • History or evidence of any clinically significant disorder, condition, or disease
  • Anticipated heart transplantation in the next 6 months
  • Has planned cardiac resynchronization therapy (CRT) or major surgery in the next 6 months
  • Serum potassium at levels identified in the protocol
  • Any persistent (2 or more) out-of-range, clinically significant safety laboratory parameters based on Central Laboratory results at enrollment
  • Hemoglobin at levels identified in the protocol
  • Serum creatine kinase at levels identified in the protocol
  • Has a ventricular assist device or ventricular assist device placement planned in the next 6 months
  • Thyroid-stimulating hormone at levels identified in the protocol
  • Has life expectancy less than 6 months
  • Is pregnant or breastfeeding
  • Is employed by or is a first-degree relative of someone employed by the Sponsor, the Investigator, or his/her staff or family
  • Other recent (<90 days) cardiovascular events (e.g., cerebrovascular accident)

Where in Spain

Also in 8 other countries, 31 sites

  • Area Sanitaria Da Coruna E CeeA Coruna, SpainTaking people
  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Bellvitge University HospitalL'hospitalet De Llobregat, SpainTaking people
  • Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
  • Hospital Universitario Virgen de la VictoriaMálaga, SpainTaking people
  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
  • Hospital Son LlatzerPalma, SpainTaking people
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people

About the trial

What the trial wants to find out

To assess the long-term safety and tolerability of danicamtiv in participants with symptomatic genetic and familial Dilated Cardiomyopathy (DCM).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
Plain-language title
Danicamtiv over the long term in adults with inherited dilated cardiomyopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
6 November 2026